Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer

Status:	Terminated
Conditions:	Lung Cancer, Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	4/21/2016
Start Date:	June 2009
End Date:	August 2013

A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology

The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab,
both in combination with carboplatin and paclitaxel in the treatment of chemonaive subjects
with recurrent or advanced non-squamous NSCLC

For additional information, please contact the BMS oncology clinical trial information
service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit
www.BMSStudyConnect.com for more information on clinical trial participation.

Inclusion Criteria:

- ECOG Performance Status (PS) <=1

- Histologically or cytologically confirmed, stage IIIB (malignant pleural effusion),
stage IV or recurrent NSCLC

- Measurable disease by RECIST guidelines

Exclusion Criteria:

- Evidence of predominantly squamous-cell histology

- Known CNS metastases

- Any prior antineoplastic systemic regimens for NSCLC

- Excessive risk of bleeding (including use of therapeutic anticoagulation) and history
of thrombotic or embolic cerebrovascular accident

- Gross hemoptysis (≥1/2 tsp of red blood)

- Uncontrolled hypertension

- Clinically significant cardiovascular disease

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within the past 6 months

- Serious non-healing wound, active peptic ulcer, non-healing bone fracture, or
bleeding skin metastasis

We found this trial at

sites

Cancer Center of Kansas

818 N. Emporia, #403
Wichita, Kansas 67214

(316) 262-4467